S'abonner

Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis - 29/07/17

Doi : 10.1016/S1470-2045(17)30516-8 
Samra Turajlic, MD a, b, , Kevin Litchfield, PhD a, , Hang Xu, PhD a, Rachel Rosenthal, MSc d, Nicholas McGranahan, PhD a, d, James L Reading, PhD c, Yien Ning S Wong, MD c, Andrew Rowan, BSc a, Nnennaya Kanu, PhD d, Maise Al Bakir, MD a, Tim Chambers, MSc a, Roberto Salgado, MD e, f, Peter Savas, MD f, Sherene Loi, MD f, Nicolai J Birkbak, PhD a, Laurent Sansregret, PhD a, Martin Gore, ProfFRCP b, James Larkin, FRCP b, Sergio A Quezada c, Charles Swanton, ProfFRCP a, d, g,
a Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London, UK 
b Renal and Skin Units, The Royal Marsden Hospital National Health Service Foundation Trust, London, UK 
c Cancer Immunology Unit, Research Department of Haematology, London, UK 
d Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, Paul O’Gorman Building, London, UK 
e Department of Pathology, Gasthuiszusters, Antwerp, Belgium 
f Division of Research and Cancer Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia 
g Department of Medical Oncology, University College London Hospitals, London, UK 

* Correspondence to: Prof Charles Swanton, Translational Cancer Therapeutics Laboratory, The Francis Crick Institute, London NW1 1AT, UK Translational Cancer Therapeutics Laboratory The Francis Crick Institute London NW1 1AT UK

Summary

Background

The focus of tumour-specific antigen analyses has been on single nucleotide variants (SNVs), with the contribution of small insertions and deletions (indels) less well characterised. We investigated whether the frameshift nature of indel mutations, which create novel open reading frames and a large quantity of mutagenic peptides highly distinct from self, might contribute to the immunogenic phenotype.

Methods

We analysed whole-exome sequencing data from 5777 solid tumours, spanning 19 cancer types from The Cancer Genome Atlas. We compared the proportion and number of indels across the cohort, with a subset of results replicated in two independent datasets. We assessed in-silico tumour-specific neoantigen predictions by mutation type with pan-cancer analysis, together with RNAseq profiling in renal clear cell carcinoma cases (n=392), to compare immune gene expression across patient subgroups. Associations between indel burden and treatment response were assessed across four checkpoint inhibitor datasets.

Findings

We observed renal cell carcinomas to have the highest proportion (0·12) and number of indel mutations across the pan-cancer cohort (p<2·2 × 10−16), more than double the median proportion of indel mutations in all other cancer types examined. Analysis of tumour-specific neoantigens showed that enrichment of indel mutations for high-affinity binders was three times that of non-synonymous SNV mutations. Furthermore, neoantigens derived from indel mutations were nine times enriched for mutant specific binding, as compared with non-synonymous SNV derived neoantigens. Immune gene expression analysis in the renal clear cell carcinoma cohort showed that the presence of mutant-specific neoantigens was associated with upregulation of antigen presentation genes, which correlated (r=0·78) with T-cell activation as measured by CD8-positive expression. Finally, analysis of checkpoint inhibitor response data revealed frameshift indel count to be significantly associated with checkpoint inhibitor response across three separate melanoma cohorts (p=4·7 × 10−4).

Interpretation

Renal cell carcinomas have the highest pan-cancer proportion and number of indel mutations. Evidence suggests indels are a highly immunogenic mutational class, which can trigger an increased abundance of neoantigens and greater mutant-binding specificity.

Funding

Cancer Research UK, UK National Institute for Health Research (NIHR) at the Royal Marsden Hospital National Health Service Foundation Trust, Institute of Cancer Research and University College London Hospitals Biomedical Research Centres, the UK Medical Research Council, the Rosetrees Trust, Novo Nordisk Foundation, the Prostate Cancer Foundation, the Breast Cancer Research Foundation, the European Research Council.

Le texte complet de cet article est disponible en PDF.

Plan


© 2017  The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 18 - N° 8

P. 1009-1021 - août 2017 Retour au numéro
Article précédent Article précédent
  • Bereaved and aggrieved in the age of social media
  • Catriona M McNeil, Martin H N Tattersall
| Article suivant Article suivant
  • Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study
  • Gemma Gatta, Riccardo Capocaccia, Laura Botta, Sandra Mallone, Roberta De Angelis, Eva Ardanaz, Harry Comber, Nadya Dimitrova, Maarit K Leinonen, Sabine Siesling, Jan M van der Zwan, Liesbet Van Eycken, Otto Visser, Maja P Žakelj, Lesley A Anderson, Francesca Bella, Innos Kaire, Renée Otter, Charles A Stiller, Annalisa Trama

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.